We offer extracorporeal membrane oxygenation (ECMO) treatments for patients suffering from cardiac and/or pulmonary failure. Based on a holistic understanding of human physiology, we develop extracorporeal life support (ECLS) technologies that can be vital for the survival of critically ill patients.[1-3]
We provide solutions combining cardiac and pulmonary support on one technological platform, the Xenios console. It supports gas exchange in the lungs and the cardiovascular system – ECMO thus provides physicians with crucial time for diagnosis and therapy. [1]
Xenios is part of Fresenius Medical Care, the world’s leading provider of products and services for people with renal diseases. As human organs are a mutually linked system, Fresenius Medical Care pursues a multi-organ support approach in Critical Care, drawing on its extensive expertise in extracorporeal blood treatment for acute kidney injury.
We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.
In our daily work, we share a passion for helping people.
For patients. Worldwide. Every day.
Visit the Xenios website:
www.xenios-ag.com
Reference:
[1] ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Extracorporeal Life Support Organization, Version 1.4 August 2017, Ann Arbor, MI, USA
[2] Peek, G. et al. (2009). Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 374(9698), 1351–1363
[3] Combes, A. et al. (2018). Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med, 378(21), 1965–1975
